Title: Serum Periostin Level in Children with Bronchial Asthma: A Comparative Study

Authors: Marwa Elhady, Mohamed Abdelmalik, Ibrahim Abu Farag, Shahinaz Elattar, Ismail Alwakil

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i1.55

Abstract

Background: Assessment of pulmonary function is important for diagnosis and monitoring of bronchial asthma. The role of biomarkers in assessment of bronchial asthma is an area of increasing interest. However, debate continues on the optimal parameters to be included and the role biomarkers play in the clinical assessment of asthma.

Aim: To evaluate the role of serum periostin level for assessment of children with bronchial asthma.

Method: this comparative study included 60 asthmatics and 30 healthy children as a control group; age and sex were matched. They were classified according to severity and level of asthma control. We investigated the correlation between serum periostin level, spirometer parameters and their relation to severity of bronchial asthma and the level of control in children. Regression analysis was done to determine risk factors for impaired pulmonary function in children with asthma.

Results: serum periostin was significantly higher in asthmatics than controls and in patients with uncontrolled compared to controlled asthma. It was significantly higher in those with severe and moderate asthma than those with mild asthma. Significant negative correlation between serum periostin level and pulmonary function parameters were detected. A logistic regression analysis showed that serum periostin level was predictor of impaired forced expiratory volume 1 (FEV1) in asthmatic children with 72.22% sensitivity and 88.1% specificity.

Conclusion: Serum periostin is a promising biomarker of treatment response and disease progression that could be used for optimization of drug doses and prediction of impaired pulmonary function in children with bronchial asthma.

Keywords- periostin, children, spirometer, bronchial asthma.

References

1.      Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. The European Respiratory Journal 2015; 46(3):622-639.

2.      Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: From benchside to clinical practice. Can Respir J 2010; 17 (4): 85-93.

3.      Chiappori A, De Ferrari L, Folli C, et al. Biomarkers and severe asthma: a critical appraisal. Clinical and Molecular Allergy : CMA. 2015;13:20.

4.      Izuhara K, Conway SJ, Moore BB, et al. Roles of Periostin in Respiratory Disorders. Am J Respir Crit Care Med. 2016;193 (9):949-56

5.      Ghalli I, Salah N, Hussein F, et al. Egyptian growth curves for infants, children and adolescents 2002. Published in: Satorio A, Buckler JMH and Marazzi N. Crecerenel-mondo 2008, Ferring Publisher, Italy.

6.      Wang Y and Chen HJ. Use of Percentiles and Z -Scores in Anthropometry. In Preedy VR (ed.), Handbook of Anthropometry: Physical Measures 29 of Human Form in Health and Disease. Springer Science, Busi-ness Media, LLC 2012. Chapter 2:P29-48.

7.      Global Initiative for Asthma. Pocket guide for health professionals. Updated 2015.

8.      Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.

9.      Bentley JK, Chen Q, Hong JY, et al. Periostin is required for maximal airways inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol. 2014;134: 1433–42.

10.  Rupani H, Lau L, Ono J, et al. Serum periostin in asthma: A potential biomarker for stratification in severe treatment-resistant asthma. European Respiratory Journal 2014; 44: P3986.

11.  Scichilone N, Crimi C, Benfante A, et al. Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics. Asthma Research and Practice 2016; 2:1

12.  Nair P, Kraft M. Serum periostin as a marker of Th2-dependent eosinophilic airway inflammation. J Allergy Clin Immunol 2012; 130:655–6.

13.  Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation is asthmatic patients. J Allergy Clin Immunol 2012: 130: 647–54.

14.  Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107: 61–67.

15.  Kanemitsu Y, Matsumoto H, Izuhara K, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013: 132: 305–12.

16.  Baek H, Izuhara K, Park T. Serum Periostin Levels Correlates with Exercise-Induced Bronchoconstriction in Asthmatic Children. Journal of Allergy and Clinical Immunology 2015, 135(2): AB151.

17.  Inoue T, Akashi K, Watanabe M, et al. Periostin as a biomarker for the diagnosis of pediatric asthma.Pediatr Allergy Immunol. 2016;27(5):521-6.

18.  Bobolea I, Barranco P, Del Pozo V, et al.Sputum periostin in patients with different severe asthma phenotypes. Allergy. 2015 May;70(5):540-6.Parulekar AD, Atik MA, Hanania NA. Periostin, a novel biomarker of TH2-driven asthma. Curr

19.  Matsumoto H. Serum periostin: a novel biomarker for asthma management. Allergol Int. 2014;63:153–160.

20.  Wadsworth SJ, Sin DD, Dorscheid DR. Clinical update on the use of biomarkers of airway inflammation in the management of asthma. Journal of Asthma and Allergy 2011:4 77–86.

Corresponding Author

Mohamed Abdelmalik

Department of Pediatrics,

Faculty of Medicine (for boys), Al-Azhar University, Cairo, Egypt